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Preclinical safety assessment of the MRI contrast agent MnDPDP serendipitously
revealed SOD activity, a potentially useful property in the treatment of several
pathological conditions. MnDPDP and its successor Ca4Mn(DPDP)5
have proceeded into clinical Phase II studies.
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Reactive oxygen species (ROS) and reactive nitrogen species (RNS)
participate in pathological tissue damage. Mitochondrial manganese
superoxide dismutase (MnSOD) normally keeps ROS and RNS in check.
During development of mangafodipir (MnDPDP) as a magnetic resonance
imaging (MRI) contrast agent, it was discovered that MnDPDP and its
metabolite manganese pyridoxyl ethyldiamine (MnPLED) possessed SOD
mimetic activity. MnDPDP has been tested as a chemotherapy adjunct in
cancer patients and as an adjunct to percutaneous coronary intervention
in patients with myocardial infarctions, with promising results. Whereas
MRI contrast depends on release of Mn2+, the SOD mimetic activity
depends on Mn2+ that remains bound to DPDP or PLED. Calmangafodipir
[Ca4Mn(DPDP)5] is stabilized with respect to Mn
2+ and has superior
therapeutic activity. Ca4Mn(DPDP)5 is presently being explored as a
chemotherapy adjunct in a clinical multicenter Phase II study in patients
with metastatic colorectal cancer.
Introduction
Aerobic organisms exist in a catch-22 situation. Oxygen sustains them, but it also poisons them
via reactive oxygen species (ROS) produced during respiration. Yet, as recently as 45 years ago,
oxygen-derived free radicals were thought to be too reactive and unselective to occur in
biological systems. That view changed dramatically when Irwin Fridovich and Joe McCord
discovered superoxide dismutase (SOD) [1], an essential cellular defense against ROS. Further-
more, all free radicals are not bad. That is particularly true for nitric oxide (NO). The biological
reaction of NO with superoxide to form the reactive nitrogen species (RNS) peroxynitrite
(ONOO) was initially proposed during the studies that characterized the chemical nature of
the endothelium-derived relaxing factor (EDRF) [2] as being NO [3–6]. Until 2005, PubMed listed
close to 50,000 papers published on SOD [7]. Few other biochemists have had such an impact on
the field of biochemistry [8].
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by a series of univalent electron transfers. Hence, intermediates
will be encountered on this univalent pathway and these are O2
,
hydrogen peroxide (H2O2) and hydroxyl radicals (OH). It is these
intermediates that are primarily responsible for the toxicity of O2
[9]. Oxidative stress can be defined as a situation where the
production of ROS and RNS out-compete the endogenous cellular
defense. There are multiple cellular sources of ROS. The most
significant ones are the electron transport complexes I and III
in the mitochondria, cytochrome P450 enzymes and NADPH
oxidase. ROS production by each of these sources can be triggered
by cytokines, inflammation, viral proteins, chemotherapy drugs,
radiation, ischemia–reperfusion and iron and copper overload.
Importantly, these processes initially generate O2
 which is
sequentially reduced to form H2O2, OH and, ultimately, H2O.
Under conditions of high oxidative stress and consequently high
production of O2
, these reactive intermediates interact with
other molecules to form secondary harmful ROS, such as lipid
peroxidation products and nitrated proteins [10–13].
In recent years, it has become evident that ROS are not merely
toxic byproducts but also serve important regulatory roles in
numerous signaling pathways. Recent findings, for example, sug-
gest that the intracellular redox environment fluctuates during the
cell cycle, shifting toward a more oxidized state during mitosis
[14,15]. After cell division, MnSOD activity increases in the G1
phase. The periodic fluctuation in MnSOD activity during the cell
cycle inversely correlates with cellular O2
, as well as glucose and
oxygen consumption [16]. On the basis of an inverse correlation
between MnSOD activity and glycolysis during the cell cycle, it is
proposed that MnSOD is a central molecular player in the Warburg
effect (i.e. the increase in glycolysis followed by lactic acid fermen-
tation as often seen in cancer cells) [17]. In general, loss of MnSOD
activity results in aberrant proliferation [14,18,19].
Knowledge about cellular oxidative stress has provided us with
important clues to treat and prevent disease. PledPharma and a few
other companies look to exploit this knowledge through develop-
ing low molecular weight SOD mimetics. During development of
mangafodipir (MnDPDP) as a magnetic resonance imaging (MRI)
contrast agent it was discovered that MnDPDP and its metabolite
manganese pyridoxyl ethyldiamine (MnPLED) possessed SOD
mimetic activity. Preclinical studies have pointed out three medi-
cal fields where MnPLED derivatives have shown promising
results: (i) cancer treatment; (ii) acute myocardial infarction
(AMI) with percutaneous coronary intervention (PCI); and (iii)
paracetamol (acetaminophen) intoxication. PledPharma has pro-
ceeded into clinical development with MnDPDP and its successor
calmangafodipir [Ca4Mn(DPDP)5] in the two first fields.
MnSOD
The manganese form of the superoxide dismutase (MnSOD) is a
homotetrameric protein found in the matrix of mitochondria,
which is closely related, in terms of sequence, to the equivalent
prokaryotic enzyme [9]. It is, however, unrelated to CuZnSOD in
the surrounding cytosol. MnSOD and CuZnSOD (cytosolic as well
as extracellular) are the most crucial enzymes in the cellular
defense against oxidative stress. They catalyze dismutation of
superoxide (O2
) to H2O2 and molecular oxygen [9]. Knockout mice
that are unable to synthesize MnSOD are severely affected and live412 www.drugdiscoverytoday.comonly a few days after birth. These mice express dilated cardiomyop-
athy that is a hallmark of chronic heart failure [20] and neurode-
generation [21]. The consequences of knocking out the cytosolic
CuZnSOD are notable but much less dramatic [22,23]. Superoxide
plays a central part in cellular production of the devastating
hydroxyl radical (OH) by its high ability to reduce ferric iron
(Fe3+) to ferrous iron (Fe2+). As mentioned above, O2
 readily reacts
with NO to form toxic ONOO, revealing the ‘ugly’ side of NO [11].
No aerobic organism survives without having the ability to
dismutate O2
. However, Lactobacillus plantarum and related lactic
acid bacteria lack SOD enzymes. In these organisms Mn2+ forms
complexes with various organic acids, including phosphoric acid,
lactic acid and carbonic acid [24–26]. The complexed Mn2+ is first
oxidized by O2
 to Mn3+. The Mn3+ thus formed is subsequently
reduced to Mn2+ by a second O2
, making the reaction a true
metal-catalyzed dismutation like that catalyzed by the SOD
enzymes. Free Mn2+ ions in non-complexing buffers, by contrast,
are poorly reactive with O2
. These Mn complexes have a high
catalytic activity and serve the same function as SOD. However, in
multicellular organisms the importance of SOD proteins is consis-
tent with a selection process favoring organisms that elaborate a
means of localizing transition metal catalyst for superoxide dis-
mutation to parts of the cell where there is a high need for such
dismutation. Results from myocardial ischemia–reperfusion in
anesthetized pigs inevitably show that the intact MnPLED, but
not manganese per se, protects against oxidative stress, seen as a
profound reduction in infarct size [27].
The biological half-life of NO is prolonged by SOD that elim-
inates O2
 at diffusion-controlled rates [9]. The rate constant of the
reaction of O2
 with NO is approximately six-times higher than
that with SOD, and therefore NO could, under certain conditions,
outcompete SOD for O2
 [10–12]. During normal conditions,
1–5% of the total cellular oxygen consumption is estimated to
leak out from the electron transport chain as O2
 [11]. The
concentration of O2
 is however kept remarkably low by SODs,
in particular by MnSOD.
NO has erroneously been described as extremely short-lived and
reactive. However, this is not true under normal cellular conditions
where NO is not more reactive than molecular oxygen [11]. Other-
wise, NO would not be able to fulfill its many important cellular
signaling tasks [28]. During inflammatory processes, however,
owing to induction of inducible nitric oxide synthase (iNOS), the
NO concentration can increase to levels high enough to outcompete
the endogenous MnSOD and CuZnSOD activities, revealing the ugly
side of NO, namely ONOO [11]. By nitrating tyrosine-34 of the
human MnSOD, ONOO irreversibly inactivates enzymatic activi-
ty, and hence causes a vicious circle that enhances the production of
ONOO further. Nitrated proteins are found in several pathological
conditions, including inflammatory process [12], chronic rejection
of human renal allografts [29], tumor-associated immunosuppres-
sion [30] and paracetamol (acetaminophen) intoxication [31].
Importantly, ONOO is not capable of directly incorporating nitrate
to the tyrosine residue but requires the contribution of a transition-
metal-dependent (probably Fe2+/Fe3+) radical pathway [11,12].
SOD mimetics
Kensler et al. described anticarcinogenic activity of the first gener-
ation of a CuSOD mimetic in 1983 [32]. They were followed by
Drug Discovery Today  Volume 20, Number 4 April 2015 REVIEWS
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and cyclic polyamine types [33,34], as well as MnPLED derivatives
[35–37]. During the development of the MnPLED derivative
MnDPDP (Fig. 1) as an MRI contrast agent at the beginning of
the 1990s, clinical studies showed that rapid intravenous injection
into patients caused cardiovascular effects and facial flushing
[38,39]. At that time, there was suspicion that these effects might
have been caused by a Ca-channel ‘blocking’ effect of Mn2+. In
1991 Matsunaga and Furchgott [40] demonstrated that low (30–
100 mM) concentrations of Mn2+, as well as Cu2+, potentiated the
vasodilator effect of photogenerated NO in endothelium-free rab-
bit aortas and suggested that the potentiating effects were due to
O2
 scavenging properties of these transition metals. On the basis
of this finding, pharmacological studies were conducted in isolat-
ed bovine mesenteric arteries (BMA) with and without endothelial
cells demonstrating that MnDPDP protected endothelium-derived
NO from being destroyed by O2
 [35,36]. These results further
suggested that this effect was the result of a SOD-mimetic activity
of MnDPDP (Fig. 2). In addition, a series of experiments in isolated
rat hearts demonstrated that clinically relevant concentrations of
MnDPDP did not cause any Ca-channel blocking effect [36].
Experiments in conscious [36] and anesthetized [41] dogs charac-
terized MnDPDP as a cardiovascular safe drug.
In line with the results of Matsunaga and Furchgott, Asplund
et al. [35] showed similar effects to MnDPDP for MnCl2. The SOD-
mimetic activity of MnCl2 was presumably caused by Mn
2+ com-
plexed to phosphoric acid and carbonic acid of the used Krebs
buffer, as described above. However, this effect of MnCl2 is not
expected to occur under in vivo conditions. The suggestion that
MnDPDP possessed SOD activity was confirmed later by electron
spin resonance (ESR) spectroscopy [37] (Fig. 3). It was furthermore
shown that the metabolite MnPLED possessed SOD mimetic ac-
tivity, whereas ZnPLED did not. It was realized that this property of
MnDPDP could be employed in therapy. In 2003, the SOD mimetic
activity of MnDPDP was confirmed by a photometric nitroblue
tetrazolium reduction method by Bedda et al. [42]. They also
demonstrated glutathione reductase as well as catalase activityO
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FIGURE 1
Chemical structure of manganese dipyridoxyl diphosphate (MnDPDP;
generic name mangafodipir), manganese pyridoxyl ethyldiamine (MnPLED)
and tetracalcium monomanganese penta(dipyridoxyl diphosphate)
[Ca4Mn(DPDP)5; calmangafodipir].of MnDPDP. However, in these experiments they used a ready-to-
use contrast formulation of MnDPDP, which in addition to 10 mM
MnDPDP also contained 6 mM ascorbic acid. Unfortunately, no
ascorbic acid control was included, which makes these results
somewhat questionable.
Another important property of MnPLED derivatives is their
high affinity for iron. The 10log formation constant [10log(KML)]
for Fe3+ and PLED is 36.88 [43], making PLED derivatives highly
efficacious inhibitors of the Fenton reaction [44]. The formation
constant for PLED is in fact six orders of magnitude higher than
that of the clinically used deferoxamine [45]. Hence, MnDPDP,
and particularly MnPLED, through their combined SOD mimetic
activities and iron-binding properties, effectively inhibit iron-
driven production of ONOO as well as that of OH.
After intravenous administration, MnDPDP is rapidly depho-
sphorylated by alkaline phosphatases into the much more lipo-
philic MnPLED [46]. Indirect evidence from in vivo studies in pigs
[27] and mice [46] suggest that MnPLED (molecular weight
520 Da) but not its somewhat larger and more hydrophilic
‘mother substance’ MnDPDP (molecular weight 680 Da) is
taken up intracellularly – which probably is a prerequisite for
the therapeutic activity. For example, the fact that MnPLED,
but not MnDPDP, protects against anthracycline cardiotoxicity
when added directly into an organ bath containing an electrically
paced mouse atrium suggests intracellular uptake of MnPLED.
Interestingly, in MnSOD-deficient Cryptococcus neoformans (an
encapsulated yeast), the SOD mimetic Mn salen exerted antioxi-
dant activity, but not MnCl2 and none of a series of cationic
and highly charged manganese porphyrins [47]. These results
suggest that efficacy depends on intracellular uptake of the
intact manganese complex. When it comes to MnDPDP, in addi-
tion to the dephosphorylation process a parallel dose-dependent
transmetallation occurs where Mn2+ is displaced by endogenous
Zn2+. Zinc has a 1000-times higher affinity than Mn2+ for DPDP
or its metabolites [43]. When an MRI dose (i.e. 5–10 mmol/kg) is
injected into humans or rats about 80% of the Mn2+ is released
from DPDP or its dephosphorylated counterparts, and only about
20% stays bound to the chelator. Release of paramagnetic Mn2+
is in fact a prerequisite for the diagnostic MRI properties of
MnDPDP [36,48], whereas the in vivo SOD mimetic activity
depends on the intact manganese complex [37].
Manganese is an essential as well as potentially neurotoxic
metal [49]. It has been known for many years that, under
conditions of chronic exposure to manganese, a syndrome of
extrapyramidal dysfunction similar to Parkinson’s syndrome
frequently occurs. The neurological symptoms correlate with
accumulation of manganese in the basal ganglia, seen as hyper-
intensity on a T1-weighted MRI [49,50]. For MRI purposes and
for occasional therapeutic use, dissociation of Mn2+ from
MnDPDP does not result in an increase in T1-weighted MRI signal
of the basal ganglia in humans [51]. However, for more frequent
use, as in therapeutic use, accumulated manganese toxicity can
represent a problem.
A considerable part of Mn2+ release from MnDPDP is governed
by the presence of a limited amount of free or loosely bound
plasma Zn2+ [46]. Replacement of 80% of Mn2+with Ca2+, gener-
ating a compound known as calmangafodipir [Ca4Mn(DPDP)5], is
enough for binding a considerable amount of the readily availablewww.drugdiscoverytoday.com 413
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FIGURE 2
The vasodilator effects of manganese dipyridoxyl diphosphate (MnDPDP) and acetylcholine (ACh) and the cyclic (c)GMP content in the isolated bovine mesenteric
artery (BMA) is shown to the left. MnDPDP or ACh was added to phenylephrine-contracted BMA rings. Tension was measured using isometric gauge transducers
and polygraphs. The cGMP content of pre-contracted arteries was determined in the absence and presence of MnDPDP or ACh. The proposed mechanism is
illustrated in the right part of the figure [35,36]. Vasodilator nitric oxide (NO) is produced by endothelial NO synthase (eNOS) in the innermost (endothelial) cellular
layer of the artery, and NO stimulates guanylate cyclase (sGC) in smooth muscle cells to produce increasing amounts of cGMP which causes relaxation and hence
vasodilation. Normally, a large fraction of NO reacts with superoxide (O2
), forming peroxynitrite (ONOO). MnDPDP preserves vasodilator NO by dismutating O2
.
ACh causes vasodilation by increasing endothelial NO production per se by a receptor-mediated process. Neither MnDPDP nor ACh causes vasodilation in the
absence of endothelial cells (EC).
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tion in the brain and other organs [52]. Zn2+ has roughly 1000-times
greater affinity than Mn2+ for DPDP [52], and replacement of Mn2+
with more loosely bound Ca2+ reduces the amount of Mn2+ released
after injection. Calcium has approximately 106 times lower affinity
than Mn2+ for DPDP [52]. Karlsson et al. [52] reported that replace-
ment of 80% of the Mn2+ with Ca2+ more than doubles the in vivo1 min
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FIGURE 3
Electron spin resonance (ESR) spectra: O2
 was generated in the xanthine oxidas
(DMPO). Control reaction (upper panel) revealed that the superoxide adduct DMPO
(4 min). 10 mM manganese dipyridoxyl diphosphate (MnDPDP; lower panel) marked
activity [37].
414 www.drugdiscoverytoday.comstability of the Mn complex, and results in significantly (40%) less
retention of Mn in the brain compared with MnDPDP (at equimolar
manganese doses) after repeated dosing (39 doses) at more than
30-times the assumed clinical dose (per dose) in rats. At equivalent
Mn2+ doses, Ca4Mn(DPDP)5 is significantly more efficacious
than MnDPDP to protect BALB/c mice against myelosuppressive
effects of the chemotherapy drug oxaliplatin (Fig. 4).4 min
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e reaction in the presence of the spin trap 5,5-dimethyl-1-pyrroline-N-oxide
-OOH evolved rapidly (within 1 min) toward the hydroxyl adduct DMPO-OH
ly reduced the signal intensity indicating superoxide dismutase (SOD) mimetic
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FIGURE 4
Myeloprotective effects of tetracalcium monomanganese penta(dipyridoxyl
diphosphate) [Ca4Mn(DPDP)5], manganese dipyridoxyl diphosphate
(MnDPDP), Teslascan (the commercial formulation of MnDPDP containing
6 mM ascorbic acid) and MnPLED (the MnDPDP metabolite), with regard to
white blood cells (WBC) [52]. BALB/c mice were treated once i.p. with
12.5 mg/kg oxaliplatin. One day before (baseline) as well as 6 days after
oxaliplatin treatment, blood samples were taken and analyzed for the
content of WBC, and other blood cells. Thirty minutes before and 24 hours
after oxaliplatin administration, mice received saline, 6.5 mmol/kg
Ca4Mn(DPDP)5 (corresponding to 1.3 mmol/kg Mn
2+), 1.3 and 13.0 mmol/kg
MnDPDP (corresponding to 1.3 and 13 mmol/kg Mn2+), 13.0 mmol/kg Teslascan
(corresponding to 13 mmol/kg Mn2+) or 2.0 mmol/kg MnPLED (corresponding
to 2 mmol/kg Mn2+) i.v.; a control group received vehicle (5% glucose) instead of
oxaliplatin and saline instead of test substance. The results are presented as
relative differences in cell counts between baseline and day six in each
treatment group. Results expressed as mean  SEM (n = 5 in each group).
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Cancer treatment
Conventional chemotherapy and radiotherapy play important
parts in palliation and cure of patients with cancer. However,
the use of chemotherapy and radiotherapy is hampered by
dose-limiting toxicity (DLT). To increase the therapeutic index
of chemotherapy and radiation therapy, researchers have tried
selectively to increase the sensitivity of tumor cells for a given
treatment and, at the same time, protect normal cells. Rescue of
normal cells through the use of cytoprotective agents could enable
a much more intense therapy. Importantly, to be clinically useful
as an adjunct to chemotherapy, a cytoprotectant should protect
normal tissue from chemotherapy-induced toxicity but not tumor
tissue (at least not to any great extent).
ROS are generated during chemotherapy with a series of struc-
turally dissimilar anticancer agents [53]. The resulting increase in
oxidative stress is believed to be a main cause of toxicity to normal
cells, in particular to rapidly dividing cells, such as myeloid and
mucosal cells. So far, two antioxidants (i.e. amifostine and dexra-
zoxane) have reached the clinic. However, their use has been
restricted. When it comes to dexrazoxane, this restriction has
mainly been due to suspicion of negative interference with theanticancer activity of chemotherapy. In addition to its cardiopro-
tective use, dexrazoxane has been approved as treatment of extrav-
asation caused by intravenous anthracycline chemotherapy [54] in
Europe and the USA. Amifostine was mainly developed as a radio-
protectant but also achieved approval for use in protection of the
kidneys from harmful effects of cisplatin in patients with ovarian
cancer. The clinical use of amifostine has been restricted as a result
of hypotension and emesis. Furthermore, concerns about tumor
protection have caused controversy regarding the appropriate use
of amifostine [55].
The anthracycline doxorubicin (Adriamycin1) is one of the best
agents for treating human hematological malignancies and solid
tumors. Its use is, however, hampered by severe cardiotoxicity,
resulting in chronic heart failure [44]. There is substantial evidence
that O2
 [56] and iron [57] play key parts in the underlying
deleterious effects. Despite decades of research and testing of
thousands of potentially protective agents, only one drug has
been approved for clinical use, namely the iron chelator dexra-
zoxane in metastatic breast cancer treatment [56]. Interestingly,
this drug is not an outcome of any sophisticated and rational drug
design. Its cardioprotective activity was discovered accidentally
during preclinical testing. However, dexrazoxane is not indicated
at the beginning of doxorubicin therapy because of suspicion that
it might reduce the anticancer effect [58].
An in vitro mouse model was employed by Towart et al. [59] to
test the cardioprotective potential of MnDPDP and other com-
pounds against doxorubicin toxicity. The toxicity is seen as a
decrease in contractility of an electrically paced mouse left
atrium. MnDPDP did not protect when added directly into the
organ bath. However, after having been intravenously injected
30 min before the mouse was killed and the left atrium was
dissected out; 1–10 mmol/kg MnDPDP was cardioprotective.
MnDPDP was shown to be about 100-times more efficacious
than dexrazoxane (i.e. 1 mmol/kg MnDPDP gave similar protec-
tion to that of 93 mmol/kg dexrazoxane). Most importantly, the
fully dephosphorylated metabolite of MnDPDP, MnPLED, was
about 100-times more efficacious than MnDPDP (unpublished
data). Furthermore, when added directly into the organ bath,
MnPLED but not MnDPDP protected against doxorubicin cardi-
otoxicity [44]. Indirectly, these results suggested that MnDPDP
undergoes in vivo dephosphorylation before it can exert the
therapeutic effect.
In vivo and in vitro experiments, utilizing human breast cancer
cells (MX-1) and ovarian cancer cells (A2780), suggested that
cardioprotection takes place without interfering negatively with
the anticancer activity of doxorubicin [44]. In vitro experiments in
fact suggested the opposite (i.e. MnDPDP exerted an anticancer
activity). In addition to the above-described potential use of
MnPLED derivatives in anthracycline-induced cardiotoxicity,
preclinical studies have demonstrated that MnDPDP protects
against myelosuppressive effects of paclitaxel [60]. This protective
effect of MnDPDP on peripheral white blood cells was accompa-
nied by a parallel protection of bone marrow cells, suggesting that
MnDPDP exerts its protective effect at the level of myelopoiesis.
Furthermore, co-administration of MnDPDP with paclitaxel
dramatically improved the survival rate of mice infected with
Staphylococcus aureus [60], revealing a possible preventive effect
on febril neutropenia, a severe DLT of many chemotherapywww.drugdiscoverytoday.com 415
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FIGURE 5
Antitumor effect of oxaliplatin in the absence and presence of Ca4Mn(DPDP)5
[52]. Briefly, syngenic BALB/c mice were injected subcutaneously in the back
of the neck with 2  106 of CT26 (BALB/c colon cancer cells) at day zero. After
7 days (day seven) when the tumors were detectable, the tumor size was
determined with a caliper and mice were grouped so that the sizes of the
tumors were not statistically different by group. 10 mg/kg oxaliplatin 6.5 or
32.5 mmol/kg Ca4Mn(DPDP)5 were injected and one group of mice received
vehicle (0.9% saline + 5% glucose) treatment alone (controls). The mice were
killed on day ten and the tumors were excised, and wet weights were
determined. Results are expressed as mean  SEM (n = 5 in each group).
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obtained without diminishing the anticancer efficacy [61]. Con-
trary, MnDPDP was shown to enhance the anticancer effect of
oxaliplatin toward colon cancer cells under in vitro and in vivo
conditions, and it displayed a distinct anticancer effect of its own
[60,61]. These authors also demonstrated that N-acetylcysteine
(NAC) had protective effects similar to those of MnDPDP but, in
opposition to MnDPDP, NAC interfered negatively with the anti-
cancer activity of oxaliplatin and paclitaxel.
The experimental SOD mimetic, MnTBAP, displayed similar in
vivo as well as in vitro anticancer activity to MnDPDP toward
murine colon cancer (CT26) cells in the presence of chemother-
apy [60]. Whereas MnDPDP protected human leukocytes toward
oxaliplatin, 5-fluorouracil and paclitaxel, MnTBAP did not.
These phenomena were paralleled with the oxidative stress
status of these cells. In the presence of oxaliplatin, 5-fluorouracil
or paclitaxel, MnDPDP increased oxidative stress in the CT26
cells but decreased it in the leukocytes, whereas MnTBAP
increased it in both cell types. The SOD mimetic activity of
MnTBAP per se has, however, been challenged and is suggested
to be caused by impurities [33].
As mentioned above, Ca4Mn(DPDP)5 was significantly more
efficacious than MnDPDP at equivalent manganese doses at
protecting BALB/c mice against myelosuppressive effects of the
chemotherapy drug oxaliplatin [52] (Fig. 4). The efficacy of
Ca4Mn(DPDP)5 was similar to that of MnPLED, at manganese
equivalent levels, suggesting that surplus CaDPDP at clinically
relevant therapeutic doses (1–5 mmol/kg) changes the metabolism
of MnDPDP in a way that considerably more MnPLED is formed.
Ca4Mn(DPDP)5 has also been shown to protect against myelosup-
pressive effects caused by carboplatin and docetaxel (unpublished
data). Similar to MnDPDP, Ca4Mn(DPDP)5 increased the antitu-
mor effect of oxaliplatin in CT26 tumor-bearing mice [52] (Fig. 5).
The reason why MnDPDP and Ca4Mn(DPDP)5 protect nonma-
lignant cells but kill cancer cells is poorly understood. One plausi-
ble explanation could be that MnDPDP and Ca4Mn(DPDP)5 in
combination with chemotherapy increase oxidative stress in can-
cer cells to a level where apoptosis is induced, whereas at the same
time lowering it in normal cells. As mentioned above, Kurz et al.
[44] showed that the in vitro cytotoxic activity of MnDPDP is an
inherent property of chelator alone and not of the intact
Mn2+complex. Speculatively, it could be that cancer cells prefera-
bly take up the dissociated chelator, whereas the intact Mn2+
complex is preferably taken up by nonmalignant cells, somewhat
in analogy with that described for amifostine [62]. Alternatively,
cancer cells might be more sensitive to the cytotoxic effect of
DPDP and PLED than normal cells. As described in the SOD
mimetic section, DPDP and PLED are strong iron chelators. That
is particularly true for PLED having a 10log (KML) of 36.88 [43],
which is six orders of magnitude higher than that of the clinically
used deferoxamine [45]. Interestingly, iron chelators are now
gaining momentum as promising drugs in cancer treatment [63].
Some other clues can be obtained from research aiming to find
selective radioprotectants. A body of evidence demonstrates that
overexpression of MnSOD protects nonmalignant tissues against
radiation-induced oxidative stress and, interestingly, simulta-
neously makes cancer cells more susceptible to radiation [64].
Recently, as mentioned above, MnSOD has been identified as416 www.drugdiscoverytoday.coma central molecular player for the Warburg effect (i.e. increase
in glycolysis followed by lactic acid fermentation as often seen
in cancer cells) [17].
Experimental as well as clinical use of SOD enzymes is restricted
owing to their large molecular weight and poor cellular uptake
[65]. To circumvent this limitation experimentally, transgenic
animal models have been used to study the radioprotective
potential of the MnSOD enzyme. These studies have demonstrated
that treating radiated animal models with MnSOD, delivered by
injection of the enzyme through liposome- or viral-mediated gene
therapy or insertion of the human MnSOD gene, can ameliorate
radiation-induced damage and simultaneously make cancer cells
more susceptible to radiation [64]. It is known that reduced
MnSOD expression contributes to increased DNA damage, and
cancer cell lines often have diminished MnSOD activity compared
with normal counterparts [14,18,19]. Mutations within the
MnSOD gene and its regulatory sequence have been observed in
several types of human cancers [14,19]. MnSOD is known to
suppress cell growth in a variety of cancer cell lines and in mouse
models. The MnSOD growth-retarding functions are at least par-
tially caused by triggering of a p53-dependent cellular senescence
program [66]. Transfection of human MnSOD cDNA into MCF-7
human breast cancer cells, UACC-903 human melanoma cells,
SCC-25 human oral squamous carcinoma cells, U118 human
glioma cells, HCT116 human colon cancer cells and DU145
human prostate cancer cells significantly suppressed their malig-
nant phenotype [52]. Introduction of the normal MnSOD gene
in cancer cells alters the phenotype and the cells lose the ability
to form colonies in culture and tumors in nude mice [67].
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part in promoting tumor metastasis [52]. These data are consistent
with the suggestion that the redox balance of epithelial tumor cells
favors an elevated oxidant set point [53], including CT26 cells
[60,61]. Although inflammatory processes secondary to oxidative
stress damage normal tissue, they can, in fact, be beneficial to
tumor tissue by creating a growth-factor-rich microenvironment
[68,69]. Moreover, not only can such a condition promote
tumor growth but it has also been shown to suppress activation
of CD8+ T lymphocytes that are most efficient in tumor elimina-
tion. In fact, there is an increasing interest regarding cytotoxic-T-
lymphocyte-mediated immune response for the outcome of
cancer chemotherapy [70–73]. It is known that severe lymphocy-
topenia (<1000 cells/ml) negatively affects the chemotherapy
response. Furthermore, a high neutrophil:lymphocyte ratio is
associated with a low overall survival for patients with advanced
colorectal cancer [71]. A collection of mouse cancers, including
CT26 colon cancer, respond to chemotherapy with doxorubicin
and oxaliplatin much more efficiently when they are implanted
in syngenic immune-competent mice as opposed to in immune-
deficient hosts (i.e. nude mice) [72]. Recently, ipilimumab
(Yervoy1; Bristol-Myers Squibb), a monoclonal antibody targeting
cytotoxic T lymphocyte antigen (CTLA)-4, received approval from
the FDA for treatment of metastatic melanoma. CTLA-4 is a
protein receptor that downregulates the immune system.
The interest for adoptive cell therapy (ACT) for cancer, in which
T lymphocytes are extracted from a cancer patient, expanded ex
vivo and re-administered to the same patient, is increasing. How-
ever, the efficacy of this approach is limited by several possible
factors, including immune suppression of CD8+ T lymphocyte
activity and tumor infiltration. The limited efficacy involves
ONOO-induced tyrosine nitration of proteins essential for T
lymphocyte function [30,73–75]. The mechanism behind immune
suppression could in fact reveal new pharmacological possibilities
to increase the efficacy of ACT. MnPLED derivatives are expected
to inhibit tyrosine nitration via two powerful mechanisms; that is,
through (i) their SOD-mimetic activities and (ii) their high affinity
for iron. In addition, this class of compounds has been shown to
possess (iii) a direct lymphocyte-protecting effect against chemo-
therapy in mice [52,60].
Acute myocardial infarction
A major concern in coronary heart disease is disabling heart failure
after AMI. This is particularly true when it comes to ST-elevated
AMI (STEMI). Current treatment by reperfusion using PCI provides
clinical benefits. However, reperfusion per se could cause consid-
erable cell death by a process known as reperfusion injury (RI),
which can account for as much as 50% of the remaining infarct.
RI is a multifaceted syndrome [76] including arrhythmias,
stunning, microvascular obstruction and necrosis. Oxidative stress
with uncontrolled release of ROS and impaired calcium homeo-
stasis followed by inflammation are the main causes of RI [76].
Previous attempts to target known mediators of myocardial RI
in patients with antioxidant therapy, calcium-channel blockers,
sodium–hydrogen exchange inhibitors and anti-inflammatory
drugs have been disappointing, leading to calls for a re-evaluation
of the current procedure for translating experimental interven-
tions into clinical therapy [77].In the late 1980s, Crompton and colleagues identified the
immunosuppressant cyclosporine as an inhibitor of the mitochon-
drial membrane permeability transition (MPT) pore [76]. Piot and
colleagues reported positive results from a clinical study involving
58 STEMI patients who were randomized to either intravenous
cyclosporine or placebo treatment [78]. Their study suggested that
the MPT pore could be a new target for reducing the myocardial
infarct size. An ongoing confirmatory Phase III study including
1000 STEMI patients randomized to either cyclosporine or
placebo (CIRCUS; ClinicalTrials.gov identifier: NCT01502774) is
estimated to be completed toward the end of 2015.
Another clinical study in STEMI patients also targeting the MPT
pore, but with another compound, TRO40303 (NCT01374321),
was completed October 2013. As recently disclosed [79], however,
no differences were observed between TRO40303 and placebo.
During the past few decades output of new drugs has in general
been low [80]. Already more than 20 years ago, Sir James Black et al.
[81] warned against this problem. This problem was, according to
him and his co-authors, caused by a paradigm shift from a physio-
logical/pharmacological one to a typical genetic sequential
approach (i.e. A gives B which in turn gives C). According to the
genetic sequential paradigm, creating a new drug is about identify-
ing the right target, in this case the MPT pore, and the corresponding
‘magic bullet’. However, according to the physiological/pharmaco-
logical paradigm life is much more complicated, where a multitude
of signals are going on in parallel, creating nonlinear systems.
It might very well be that attacking the oxidative stress upstream
of the MPT pore is a much more efficacious approach when it
comes to combating reperfusion injuries in the heart.
By making use of ESR spectroscopy Garlick and colleagues were
able to show directly that re-oxygenation of a globally hypoxic ex
vivo heart resulted in a sudden burst of oxygen-derived free radicals
[82]. Bolli et al. [83], by also making use of ESR spectroscopy, were
able to demonstrate direct in vivo evidence in dogs that reperfusion
resulted in a burst of oxygen-derived free radicals. Treatment with
a mixture of SOD and catalase (CAT) attenuated the burst. Inter-
estingly, plasma 8-iso-PGF2a, a biomarker of oxidative stress, has
been shown to peak 15 min after acute PCI in patients, whereas the
biomarker of irreversible injury, plasma cTnT, peaked first after
6 hours [84]. This suggests a therapeutic window upstream of the
MPT pore for a compound with SOD activity.
The idea of using SOD enzymes as adjuncts to reperfusion
therapy was born in the 1980s. Preclinical studies using SOD alone
or in combination with CAT showed, however, conflicting results
[85]. The rationale of using SOD in combination with CAT is that
the latter takes care of H2O2 formed during cellular dismutation
of O2
. CAT catalyzes cellular decomposition of H2O2 into H2O
and O2. Superoxide (O2
) participates in the devastating Fenton
reaction (Fe2+ + H2O2 + H
+ ! Fe3+ + OH + H2O) by reducing Fe3+
back to Fe2+. The hydroxyl radical (OH) is probably the most
devastating of all cellular formed ROS and RNS. Nevertheless, in
several studies, addition of CAT was not felt necessary in vivo
because of the presence of significant amounts in CAT-containing
erythrocytes [85]. The conflicting results concerning whether or
not SOD protects against ischemia–reperfusion injury could be due
to the size of the enzyme which most presumably rules out
intracellular uptake and access to the most crucial cellular com-
partments. Indirect evidence from studies in pigs [27] and micewww.drugdiscoverytoday.com 417
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cellularly.
Initial experiments in ex vivo rat hearts showed that MnDPDP
significantly improved contractile function and reduced enzyme
release lactate dehydrogenase (LDH) in hearts subjected to hypox-
ia-reoxygenation [37]. In anesthetized pigs with occlusion of the
anterior descending branch of the left coronary artery (LAD) for
30 min and reperfusion for 120 min, MnPLED reduced infarct size
by more than 50% (Fig. 6) [27]. MnPLED also improved cardiac
function and abolished reperfusion-induced ventricular fibrilla-
tion. In this study, MnPLED was applied as an intravenous bolus at
the end of ischemia followed by a continuous infusion over
120 min. The failure of MnDPDP to reduce the infarct size in this
study is presumably caused by the fact that no or very little of the
injected MnDPDP is transformed into MnPLED in the pig [27]. This
is in contrast to humans, dogs and rats where about 30% of
MnDPDP is present as MnPLED 5–30 min after injection [46].
Liver toxicity caused by paracetamol (acetaminophen) and
ischemia–reperfusion
Paracetamol (acetaminophen) is a commonly used drug, and is the
most prevalent cause of drug-induced acute liver failure [86].
Progression to hepatic failure is characterized by development
of encephalopathy, coma, cerebral edema, coagulopathy, gastro-
intestinal bleeding and sepsis. The mortality rate is high. When
given up to 8 hours after ingestion, NAC offers almost complete
protection against developing acute liver failure, whereas more
than 50% of retrospectively studied patients who only receivedIn
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FIGURE 6
Infarct size in anesthetized pigs, expressed as % of area at risk [27]. Briefly, the
left anterior descending artery (LAD) was dissected free between the second
and third diagonal branches. After an initial 10-min recording, the LAD was
occluded by a vascular clamp. After another 20 min, the pigs received
3 mmol/kg manganese dipyridoxyl diphosphate (MnDPDP) or 1 mmol/kg
manganese pyridoxyl ethyldiamine (MnPLED) as a an i.v. injection followed
by an i.v. infusion of 3 mmol/kg/hour MnDPDP or 1 mmol/kg/hour MnPLED
throughout the experiment. To clarify whether MnDPDP (or a metabolite)
interferes with the cardioprotective effects of MnPLED, an additional group of
animals received a mixture of 3 mmol/kg b.w. MnDPDP and 1 mmol/kg
MnPLED followed by an infusion of 3 mmol/kg/hour MnDPDP and 1 mmol/kg/
hour MnPLED. Thirty minutes after the start of occlusion, the LAD was
reperfused by removal of the vascular clamp. After another 120 min, the pigs
were killed by an overdose of KCl, the heart excised and the area at risk and
infarct sizes was histologically determined, with fluorescent cadmium sulfide
microspheres and tetrazolium staining, respectively.
418 www.drugdiscoverytoday.comsupportive care developed severe liver damage [86,87]. After
8 hours, however, the antidote effect of NAC gradually fades
and after 15 hours it gives no protection. An obstacle to achieve
optimal protection with NAC is that 4–6 hours following a para-
cetamol overdose patients can be asymptomatic. This often results
that NAC treatment is started after the crucial ingestion–treatment
period of 8–15 hours has been passed. According to Prescott et al.
[87], as many as 37% of patients started NAC treatment 10–
24 hours after paracetamol ingestion.
Paracetamol-induced hepatocyte death in mice occurs by two
phases: a metabolic phase and an oxidative phase [88,89]. The
metabolic phase occurs with glutathione (GSH) depletion, and the
subsequent oxidative phase occurs with increased oxidative stress,
ONOO-mediated protein nitration and inactivation of endoge-
nous MnSOD, loss of mitochondrial membrane potential and
hepatocyte death. Experiments in mice suggest that NAC offers
protection when administered up to 2 hours after a toxic dose of
paracetamol but not after 4 hours [90].
Bedda et al. [42] reported that 10 mg/kg (13 mmol/kg) MnDPDP
administered 6 hours after a toxic dose of paracetamol protected
mice, whereas NAC did not. NAC and MnDPDP protected when
administered 2 hours before paracetamol. The fact that MnDPDP
showed protective efficacy in mice as long as 6 hours after admin-
istration of a toxic paracetamol dose suggests that MnDPDP can
offer liver protection during the oxidative phase, at a time-point
when NAC has lost efficacy. These authors also presented con-
vincing evidence that MnDPDP more or less abolished paraceta-
mol-induced necrosis and apoptosis. Paracetamol is known to
cause opening of MPT pores and breakdown of the mitochondrial
membrane potential, which leads to ATP depletion and cell death
by apoptosis and necrosis [88]. Interestingly, MnDPDP has been
shown to inhibit the MPT pores and subsequent apoptosis [91].
Thus, strong preclinical evidence points to MnDPDP as an effica-
cious remedy in paracetamol intoxication. ROS play a central part
in contributing to tissue injury after reperfusion of the ischemic
liver. Coriat and co-workers [92] have shown that MnDPDP pre-
vented experimental hepatic ischemia–reperfusion injuries in the
mouse as indicated by a reduction in serum aspartate aminotrans-
ferase (ASAT) activity, and in markers of apoptosis.
SOD mimetics: clinical activities
There are four major types of manganese-based SOD mimetics,
namely the porphyrin, cyclic polyamine, salen [33,34] and PLED
types [35–37]. The porphyrin type is developed by Aeolus Phar-
maceuticals (Mission Viejo, CA, USA). This company develops
AEOL 10150, a Phase I clinical trial lead product for various
indications, primarily as a medical countermeasure against the
effects of acute radiation syndrome in the lungs and gastrointesti-
nal tract. In January 2014, AEOL 10150 was granted an orphan
drug designation for treatment of patients with acute radiation
syndrome (ARS) (http://investor.aeoluspharma.com/releases.cfm).
The cyclic polyamine type is developed by Galera Therapeutics
(Malvern, PA, USA). At present, its lead candidate – the polyamine
compound GC4419 (previously known as M40419) – is in a Phase I
clinical trial as an adjunct to chemotherapy and radiation
treatment for squamous cell cancer (a Phase I dose-escalation study
of GC4419 in combination with chemoradiation for squamous
cell cancer of the head and neck, ClinicalTrials.gov identifier:
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of compounds is in clinical development. When it comes to the
PLED types, MnDPDP (mangafodipir) was originally developed as a
contrast agent for MRI by Salutar (Sunnyvale, CA, USA), and
achieved clinical approval in 1997. It was withdrawn from the
market in 2010. The withdrawal was not based on any safety
concerns. Nevertheless, during its time on the market more than
200,000 patients received it as a contrast agent (according to the
producer).
Before the withdrawal, PledPharma initiated a feasibility study
with MnDPDP in colon cancer patients on adjuvant treatment
with folinate + 5-fluorouracil + oxaliplatin (FOLFOX; MANFOL
study). Because of concerns that repeated use of MnDPDP could
result in manganese accumulation in the brain and cause toxic
effects, MnDPDP was only included in three out of 12 scheduled
FOLFOX cycles, and at an accumulated dose of 6 mmol/kg previ-
ously shown to be safe with regard to brain accumulation [51]. In
this study, Karlsson et al. [93] confirmed previous preclinical
findings, namely that pretreatment with MnDPDP lowers DLT
[44,59,60].
Oxaliplatin in combination with 5-fluorouracil has improved
survival considerably in colorectal cancer patients [93]. However,
the efficacy of this combination is compromised by toxicity, in
particular oxaliplatin-induced sensory neuropathy. The use of
intravenous calcium and magnesium (Ca/Mg) for prevention of
oxaliplatin-induced sensory neuropathy became a common clini-
cal practice after a report in 2004 that compared a series of patients
treated with Ca/Mg with a historical control group suggesting that
Ca/Mg decreased neuropathy by about 50% [94]. However, a
confirmatory Phase III clinical trial determined that this treatment
was ineffective [95]. Recently, Coriat et al. [96] provided results
from a Phase II clinical trial using MnDPDP in patients with pre-
existing oxaliplatin-induced neuropathy. The trial involved 22
patients with at least grade 2 sensory neuropathy after receiving
oxaliplatin. After four additional cycles of oxaliplatin and
MnDPDP, they reported that 17 patients had stable or improved
neuropathy, and after eight cycles six patients had improvement
in their neuropathy grade.
The paper by Coriat et al. [96] reported that the mean plasma
manganese content increased from 11.8  5.5 nM to 19.8  4.3 nM
after eight cycles of MnDPDP co-treatment. Although plasma
manganese is considered as a weak predictor of manganese-in-
duced neurotoxicity [50], this finding could in fact indicate an
unacceptable high brain exposure for manganese released from
MnDPDP. Furthermore, the paper by Coriat et al. confirmed the
findings of Yri and co-workers, published as a case report in 2009
[97]. This report described a patient who underwent 15 palliative
cycles of oxaliplatin plus 5-fluorouracil. In 14 of the cycles the
patient was pretreated with MnDPDP. The patient received a
cumulative dose of 15  85 mg/m2 of oxaliplatin, which is a dose
expected to cause sensory neuropathy. No symptoms of sensory
neuropathy were detected, except in the fifth cycle, when
MnDPDP was deliberately omitted, at which time the patient
experienced sensory neuropathy. Although this reference was
not included in the paper by Coriat et al. [96], both publications
suggest that MnDPDP, probably as a result of its SOD mimetic
activity, protects against oxaliplatin-induced sensory neuropathy.
The patient in the case report of Yri et al. [97] received a dose of10 mmol/kg at each of 14 cycles of chemotherapy, resulting in an
accumulated dose of 140 mmol/kg. The overall clinical impression
from this patient was positive, but an MRI scan of the brain after 14
cycles of MnDPDP showed increased T1-weighted signal intensity
in the basal ganglia. This patient manifested symptoms similar
to those previously seen in patients administered manganese-
supplemented total parenteral nutrition [49,50].
PledPharma is at present testing Ca4Mn(DPDP)5 (calmangafo-
dipir, PledOx1), a stabilized form of MnDPDP with superior ther-
apeutic index [52] in an ongoing Phase II study (PLIANT study),
which will include around 150 colon cancer patients. Before
withdrawal of MnDPDP, PledPharma also initiated a feasibility
study (MAMAMI study) in patients with acute STEMI going
through PCI. The MANAMI study included ten patients random-
ized to MnDPDP and ten patients randomized to placebo treat-
ment; and with an ischemic time (chest pain) less than 6 h. The
study was recently reported to the Swedish Competent Authority,
La¨kemedelsverket and a manuscript describing major findings has
been accepted for publication [98]. The ischemic time was signifi-
cantly longer in the MnDPDP group than the placebo group
(195 min vs 144 min). Despite this difference there were several
findings suggesting that MnDPDP in fact could protect the human
heart against reperfusion injuries, similar to that previously shown
with MnPLED in pigs [27]. The most consistent finding in the
study was a borderline statistical difference (P = 0.0383, one-sided
Mann–Whitney) in ST-resolution (STR), in favor of MnDPDP. It
is well established that early and complete STR is a powerful
predictor of infarct-related artery patency, preserved microvascu-
lar integrity and low mortality in patients with STEMI [99].
Concluding remarks and future prospects
MnPLED derivatives possess pharmacological properties which
makes them efficacious as therapeutic agents during conditions
of pathological oxidative stress. They are small and lipophilic
enough for entering crucial intracellular compartments. By dis-
mutating O2
, MnPLED derivatives attack ‘the root cause’ of the
problem (i.e. at the uppermost level of the chain of biochemical
events that leads to cell death during oxidative stress). By high
affinities for iron (and copper) they also attack further downstream
by inhibiting ONOO-mediated tyrosine nitration (e.g. of endog-
enous MnSOD) and formation of OH.
Preclinical studies have pointed out (i) cancer treatment, (ii)
acute myocardial infarction and (iii) paracetamol (acetamino-
phen) intoxication as particularly interesting fields of use.
MnPLED derivatives have entered clinical Phase II trials for (i)
and (ii), and Ca4Mn(DPDP)5 is at present being tested as an adjunct
to FOLFOX treatment in patients with metastatic colorectal cancer
in a multicenter Phase II study.
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